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Abstract
Background: Daclatasvir (DCV) is an NS5A replication complex inhibitor recently approved for chronic hepatitis C
virus treatment.
Methods: To assess drug interactions between the HIV integrase strand transfer inhibitor dolutegravir (DTG) and
DCV, subjects were randomized into 1 of 2 sequences in an open-label, 3-period, crossover study. Subjects received
either DTG 50 mg once daily or DCV 60 mg once daily for 5 days in periods 1 and 2 and DTG 50 mg plus DCV
60 mg once daily for 5 days in period 3, with no washout between periods 2 and 3. Between periods 1 and 2,
there was a washout period of at least 7 days.
Results: The geometric least-squares mean ratios (90 % confidence intervals) of DCV area under the
concentration-time curve over a dosing interval (AUC0-τ), maximum observed concentration (Cmax), and
concentration at the end of the dosing interval (Cτ) were 0.978 (0.831–1.15), 1.03 (0.843–1.25), and 1.06 (0.876–1.29),
respectively, when DCV was administered with DTG compared with DCV alone. Compared with DTG alone,
coadministration of DTG with DCV increased DTG AUC0-τ, Cmax, and Cτ by approximately 33, 29, and 45 %,
respectively.
Conclusions: DCV plasma exposure was not meaningfully affected by DTG. Coadministration of DTG with DCV
resulted in slight increases in DTG AUC0-τ, Cmax, and Cτ. Accumulated safety and tolerability data in humans
receiving DTG to date suggests this effect is not considered clinically significant. DTG and DCV can be
coadministered without dose adjustment.
Trial registration: Registered on March 6, 2014 with ClinicalTrials.gov; registration number: NCT02082808 and as
Study ID: 201102 on the ViiV Clinical Study Registry.
Keywords: Adult medicine, Drug interactions, Infectious disease, Interactions, Pharmacokinetics
Background
HIV and hepatitis C virus (HCV) are both blood-borne
viruses, with transmission in adults occurring primarily
through injection drug use or sexual contact. Both HIV
and HCV can also be transmitted from mother to child
during birth or through breastfeeding. Viral infection
can also occur in rare circumstances when virally
infected bodily fluids come into contact with a nonin-
fected person’s bloodstream, mucous membranes, or
damaged tissue such as through use of contaminated
needles or other medical equipment, transfusion of
virally contaminated blood or blood products, or various
other routes [1, 2]. Coinfection with both HIV and HCV
is not uncommon because of shared transmission
modes. Globally, approximately 7 million people are
thought to be coinfected with both HIV and HCV and,
in the United States, about one-quarter to one-third of
HIV-infected individuals are estimated to be coinfected
with HCV [3]. Infection with HCV can result in long-
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term illness and death, and viral hepatitis progresses faster
and causes more liver-related health problems among
people living with HIV than among those without HIV
infection. Although combination antiretroviral therapy
has extended the life expectancy of people with HIV, liver
disease has become the leading cause of non-AIDS-
related deaths in this population, and HIV-infected people
coinfected with HCV are at increased risk for serious, life-
threatening complications [3–5]. Treatment for HCV
infection has made remarkable progress in the last several
years, from treatments with relatively low cure rates that
typically included pegylated interferon alfa in combination
with ribavirin, to all-oral, direct-acting antiviral regimens
that produce sustained viral responses with cure rates
exceeding 90 % for many patient populations [5].
Dolutegravir (DTG, Tivicay®, ViiV Healthcare, Research
Triangle Park, NC) is an HIV-1 integrase strand transfer
inhibitor approved by the Food and Drug Adminis-
tration and the European Medicines Agency for the
treatment of HIV-1 infection in a broad patient popula-
tion [6, 7]. Daclatasvir (DCV, Daklinza™, Bristol-Myers
Squibb, Princeton, NJ) is an inhibitor of the HCV
nonstructural protein NS5A and has been approved by
the European Medicines Agency for use in combination
with other medicinal products across genotypes 1, 3, and
4 for the treatment of chronic HCV infection in adults
and by the Food and Drug Administration for the
treatment of chronic HCV genotype 3 infection in adults
[8, 9]. Because DTG and DCV may be concomitantly
administered in subjects coinfected with HIV-1 and
HCV, a drug interaction study between DTG and DCV
was warranted to evaluate the pharmacokinetics (PK) of
both drugs, as well as patient safety and drug tolerability
when these drugs are coadministered.
Methods
Study design and subjects
This was an open-label, 3-period, crossover study con-
ducted at a single-center in healthy adult subjects. The
study protocol, amendments, and consent forms were
reviewed and approved prior to study initiation by the
study site’s institutional review board (Quintiles Early
Clinical Development, Overland Park, KS, USA), and all
subjects provided their written consent prior to initiation
of any study-specific procedures. The study was con-
ducted in a manner consistent with good clinical practices
and local regulatory requirements and in accordance with
the ethical standards of the Declaration of Helsinki and its
amendments,
Adult men and women ranging from 18 to 65 years of
age with a body mass index ranging from 18.5 to 31.0 kg/
m2 (inclusive) and no clinically significant abnormalities
on the basis of physical examination, laboratory testing,
12-lead electrocardiogram, and medical history were
eligible for study inclusion. Eligible female subjects had
negative results on human chorionic gonadotropin preg-
nancy tests. Male or female subjects who were not sur-
gically sterile/postmenopausal agreed to use nonhormonal
contraceptive methods, including abstinence, an intrauter-
ine device, or 2 forms of barrier contraception. Excluded
subjects were those with a preexisting condition that
interfered with normal gastrointestinal motility or ana-
tomy; as well as subjects with hepatic dysfunction or renal
dysfunction, or both that could have interfered with the
study drugs’ absorption, metabolism, or excretion. Subjects
were excluded if they had an average weekly alcoholic
beverage intake of more than 14 drinks for males or more
than 7 drinks for females within 6 months of the study
start. Exclusion criteria also included the regular use of
tobacco- or nicotine-containing products within 6 months
prior to screening; or a positive test for HCV antibody,
hepatitis B surface antigen, or HIV antibody. Eligible
subjects were prohibited from ingesting any prescription or
nonprescription drugs, including herbal and dietary supple-
ments and vitamins within 30 days, 5 half-lives, or twice
the duration of the biological effect of the investigational
product, whichever was longer, before the first dose of
study medication.
Twelve healthy male or female subjects were enrolled
to provide data from at least 10 evaluable subjects. The
sample size of 12 to obtain 10 evaluable subjects was
chosen based on an expected withdrawal rate of appro-
ximately 10 % and the within-subject variability of DTG.
Within-subject variability of DCV, based upon historical
data, is lower than that of DTG. Using a within-subject
variability (CVw) of 30 % and a sample size of 10
evaluable subjects, it was estimated that the precision
for the treatment comparison would be within 25.8 % of
the point estimate for the concentration-time curve over
the dosing interval (AUC[0-τ]), Cmax, and Cτ. If the point
estimate of the ratio of geometric means was 1, then the
90 % confidence interval would be approximately 0.79 to
1.26. Subjects were randomized into 1 of 2 treatment
sequences (n = 6 in each sequence) according to a
randomization schedule. Study medications were DTG
as a 50-mg tablet given once daily and DCV as a 60-mg
tablet given once daily. Subjects in sequence 1 received
DTG for 5 days in period 1 (treatment A), followed by
DCV for 5 days in period 2 (treatment B), and finally
DTG plus DCV for 5 days in period 3 (treatment C).
Those in sequence 2 received DCV (treatment B) for
5 days in period 1, followed by DTG (treatment A) for
5 days in period 2, and then DTG plus DCV for 5 days
in period 3 (treatment C). All doses of study drug were
ingested under fasting conditions. Between period 1 and
period 2, there was a washout period of at least 7 days.
There was no washout period between period 2 and
period 3. Day 1 of period 3 started the day after the last
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day in period 2. Periods 1, 2, and 3 were conducted on an
inpatient setting. Within 7 to 14 days after the last dose of
study drug was taken, a follow-up visit was conducted.
The safety evaluations performed during the study
included clinical laboratory tests (hematology, serum
chemistry, and urinalysis), vital sign monitoring, and phys-
ical examinations. Electrocardiograms were performed at
screening. Throughout the entire treatment phase and at
the follow-up evaluation, there was close monitoring for
all adverse events (AEs).
Pharmacokinetic assessments
Blood samples were collected (2 mL per collection) at
predose (within 15 min prior to dosing) and at 1, 2, 3, 4,
8, 12, and 24 h postdose on day 5 in period 1 or 2 and
in period 3 for the determination of plasma concen-
trations of DTG. Blood samples were collected for the
determination of plasma concentrations of DCV using
the same sample collection schedule as was used in prior
drug-drug interaction studies with DCV [10], which was
4 mL per collection at predose (within 15 min prior to
dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h
postdose on day 5 in period 1 or 2 and in period 3.
Blood samples were drawn into potassium ethylenedi-
aminetetraacetic acid (K2 EDTA)-containing tubes via
venipuncture or through a cannula and were kept chilled
on ice until centrifugation. Plasma was separated by
centrifugation at 4 °C within 45 min of sample collection
and stored at−20 °C or below until analysis.
Bioanalytical methods
Plasma samples were analyzed for DTG concentrations
by PPD (Middleton, WI). All samples were received
frozen on dry ice and in acceptable condition and stored
frozen at−20 °C upon arrival. The DTG analysis was done
using a validated analytical method based on protein pre-
cipitation using acetonitrile, which was followed by high-
performance liquid chromatography with tandem mass
spectrometry analysis using positive-ion electrospray,
which was based on previously published methods [11].
This assay was validated over the DTG concentration
range of 20.0 to 20,000 ng/mL using a 25-μL aliquot of K2
EDTA-treated plasma.
Plasma samples were analyzed for DCV concentrations
by Tandem Labs (West Trenton, NJ, USA). Analysis was
performed using a validated analytical method of solid
phase extraction, followed by high-performance liquid
chromatography with tandem mass spectrometry analysis,
which was based on a previously published method [12].
The lower and higher limits of quantification were
2.00 ng/mL and 2000 ng/mL, respectively, using a 100-μL
aliquot of K2 EDTA-treated plasma.
Quality control (QC) samples containing 3 different
analyte concentrations of DTG and DCV were analyzed
with each batch of samples against separately prepared
calibration standards that were stored under the same
conditions as study samples. Quality control results met
acceptance criteria; ≤33 % of the quality control results
were to deviate from the nominal concentration by
>15 %, with ≥50 % of the quality control results accept-
able at each concentration. The calibration standard
coefficient of variance (CV) for DTG was ≤6.7 % with a
difference from theoretical of ≤4.9 %, and the interassay
CV per run was ≤5.8 % with a difference from theoret-
ical of ≤3.2 %. The between-run CV for DCV was
≤2.2 %, and the within-run CV was ≤2.0 % with a mean
deviation from nominal concentration of ±3.6 %.
Pharmacokinetic data analysis
Plasma DTG and DCV concentration-time data were
analyzed by noncompartmental methods using Phoenix
WinNonlin version 6.3 (Pharsight Corporation, St. Louis,
MO). Pharmacokinetic parameter calculations were based
on the actual sampling times recorded during the study.
Pharmacokinetic parameters that were determined in-
cluded maximum observed concentration (Cmax), concen-
tration at the end of the dosing interval (Cτ), AUC0-τ,
apparent clearance following oral dosing (CL/F), and
terminal phase half-life (t1/2).
Statistical analysis
Statistical analysis was performed on the log-transformed
plasma PK parameters. Point estimates and their asso-
ciated 90 % confidence intervals (CIs) were constructed
for the differences between test and reference treatments.
Dolutegravir (treatment A) or DCV (treatment B), when
given alone under fasted conditions, was considered to be
the reference treatment. The test treatments were DTG
coadministered with DCV (treatment C) under fasted
conditions. The point estimates and their associated 90 %
CIs were back-transformed to provide the ratios of
geometric least-squares means and associated 90 % CIs
for test/reference for the PK parameters AUC0-τ, Cτ, Cmax,
CL/F, and t1/2. Dolutegravir and DCV PK were analyzed
separately using SAS (SAS Institute, Inc, Cary, NC).
Results
Subject demographics and accountability
A total of 12 subjects (6 in each sequence) were enrolled
in the study, and all subjects completed study treatments
and planned DTG and DCV PK sampling. One subject
was lost to follow-up. There were no subjects who were
prematurely withdrawn from the study due to AEs.
Subjects had an overall mean age and body mass index
of 32.3 years (standard deviation [SD]: 10.1) and 24.0 kg/
m2 (SD: 3.0), respectively. The majority were male
(75 %), and white and African-American subjects each
accounted for 50 % of the total.
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Safety evaluation
Dolutegravir alone (50 mg once daily), DCV (60 mg
once daily), and DTG plus DCV (50 mg once daily and
60 mg once daily, respectively) were well tolerated. No
pattern of AE frequency was seen with respect to treat-
ment, and none of the AEs were grade 2 or greater in
severity or were considered to be drug-related. Two AEs
were reported by subjects when taking DTG alone, 1 AE
was reported by a subject taking DCV alone, and 2 AEs
were reported when DTG and DCV were taken concur-
rently. Only 1 AE, headache, was reported more than
once and it was reported 3 times, once with each treat-
ment. There were no consistent, treatment-related, or
clinically significant changes in median or mean clinical
chemistry or hematology values observed in this study,
and no clinically significant changes in electrocardio-
gram results or vital signs. After period 3 had been
completed and during the follow-up visit, one African-
American male subject had a grade 2 glucose measure-
ment of 8.05 mmol/L (144.9 mg/dL). This subject, on
one prior measurement during period 2, day−1, had a
grade 1 glucose elevation of 6.22 mmol/L (112 mg/dL)
that occurred after he completed DCV dosing and
before he received DTG. Attempts to contact him after
follow-up for additional follow-up testing were unsuc-
cessful, and he was considered lost to follow-up.
Pharmacokinetics of DTG
The mean plasma concentration-time profiles of DTG
after administration of DTG alone and in combination
with DCV are presented in Fig. 1. Coadministration of
DTG 50 mg once daily with DCV 60 mg once daily
increased DTG AUC0-τ, Cmax, and Cτ by 33, 29, and 45 %,
respectively, compared with DTG administered alone.
Dolutegravir CL/F decreased by 25 %, while the t1/2
increased by 17 % when coadministered with DCV
compared with DTG administered alone (Table 1).
Pharmacokinetics of DCV
The plasma concentration-time profiles after adminis-
tration of DCV alone and in combination with DTG are
presented in Fig. 2. DCV exposure did not appear to be
meaningfully affected by coadministration with DTG
50 mg once daily (Table 2). DCV AUC0-τ, decreased by
2.2 %, Cmax increased by 3 %, and Cτ increased by 6 %
compared with DCV administered alone. DCV CL/F


















0 5 10 15 20 25
Planned relative time, hours post dosing
DTG 50 mg q24h × 5 days
DTG 50 mg q24h + DCV 60 mg q24h × 5 days
Fig. 1 Mean plasma concentration-time profiles of dolutegravir (DTG) administered with and without daclatasvir (DCV). Abbreviations:
q24h, every 24 h; SD, standard deviation
Table 1 Statistical comparison of DTG PK parameters when administered with and without DCV







DTG + DCV vs
DTG alone
AUC0-τ (hr · μg/mL) 35.7 (34.7) 47.3 (26.3) 1.33 (1.11–1.59)
Cmax (μg/mL) 2.65 (32.0) 3.43 (24.5) 1.29 (1.07–1.57)
Cτ (μg/mL) 0.771 (41.3) 1.11 (36.6) 1.45 (1.25–1.68)
CL/F (L/hr) 1.40 (34.7) 1.06 (26.3) 0.753 (0.627–0.905)
t1/2 (hr) 13.9 (32.8) 16.2 (32.6) 1.17 (1.01–1.35)
Abbreviations: AUC0-τ area under the concentration-time curve over the dosing interval, Cτ concentration at the end of the dosing interval, CI confidence interval,
CL/F apparent clearance following oral dosing, Cmax maximum observed concentration, DCV daclatasvir, DTG dolutegravir, PK pharmacokinetic, t1/2 terminal
phase half-life
Treatment A = DTG 50 mg once daily; treatment C = DTG 50 mg once daily plus DCV 60 mg once daily
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coadministered with DTG compared with DCV admi-
nistered alone.
Discussion
The results from this study demonstrated that plasma
exposure of DCV did not appear to be meaningfully
affected when coadministered with DTG as compared
with DCV administered alone. This result is consistent
with the preclinical findings for DCV and DTG. Dacla-
tasvir is a substrate of cytochrome P450 (CYP) 3A4 and
the transporter P-glycoprotein (P-gp) [8, 9]. In vitro,
DTG demonstrates minimal or no direct inhibition of
CYP isozymes or of P-gp; and DTG is not considered an
inducer of CYP3A4 [13].
Coadministration of DTG with DCV increased DTG
AUC0-τ, Cmax, and Cτ by approximately 33, 29, and 45 %,
respectively, compared with DTG administered alone.
Dolutegravir is metabolized primarily through UDP-
glucuronosyltransferase 1A1 with a minor component
(~10 %) via CYP3A4 and is a substrate of P-gp and
breast cancer resistance protein (BCRP) [8]. Daclatasvir
is an inhibitor of some transporters, including P-gp, and
BCRP [9], which provides a reasonable mechanistic
explanation of the effect on DTG plasma exposure from
the current study. However, the effect of DCV on
increasing DTG plasma exposure is not considered
clinically significant and does not confer significant
safety risks as the increased DTG levels remain in the
range previously observed in the dose-ranging clinical
trial with HIV-1-infected subjects. In that trial, which
evaluated 2, 10, and 50 mg once-daily DTG dosing, the
ratios for AUC0-τ, Cmax, and Cτ after 10 days of admi-
nistration were estimated to be 1.25 to 1.43, 1.23 to 1.40,
and 1.27 to 1.42, respectively [14]. Similarly, in the
VIKING-3 and−4 studies, integrase-resistant, HIV-
infected patients received 50 mg of DTG twice daily,
and predose (C0) DTG concentrations were obtained at
day 8 and at weeks 4 and 24 [15, 16]. The geometric
mean and between-subject CV% for the DTG C0 in
VIKING-4 was 1.80 μg/ml (123 %; n = 27) at day 28 and
2.05 μg/ml (127 %; n = 24) at week 24; comparable to
those observed in VIKING-3 at week 4 (1.90 μg/ml
[113 %; n = 161]) and week 24 (2.14 μg/ml [93 %; n =
134]). There have been no apparent differences in safety
profiles across DTG doses evaluated in phase IIb/III
studies, and DTG is well tolerated in HIV-1-infected
subjects, with no dose-limiting toxicity observed to date
[15–23]. An upper limit of exposure associated with an
increased incidence of AEs or significant clinical chemis-



















0 5 10 15 20 25
Planned relative time, hours post dosing
DCV 60 mg q24h × 5 days
DCV 60 mg q24h + DTG 50 mg q24h × 5 days
Fig. 2 Mean plasma concentration-time profiles of daclatasvir (DCV) administered with and without dolutegravir (DTG). Abbreviations:
q24h, every 24 h; SD, standard deviation
Table 2 Statistical comparison of DCV PK parameters when administered with and without DTG
Plasma DCV PK parameter Geometric mean (CV%) Geometric least-squares mean ratio (90 % CI)
DCV alone (treatment B)
(N = 12)
DCV + DTG (treatment C)
(N = 12)
DCV + DTG vs DCV alone
Cmax (μg/mL) 1.19 (42.6) 1.22 (42.2) 1.03 (0.843–1.25)
AUC0-τ (hr · μg/mL) 11.4 (47.9) 11.2 (41.6) 0.978 (0.831–1.15)
Cτ (μg/mL) 0.166 (69.3) 0.176 (53.8) 1.06 (0.876–1.29)
CL/F (L/hr) 5.25 (47.9) 5.36 (41.6) 1.02 (0.868–1.203)
t1/2 (hr) 8.58 (23.2) 8.42 (29.4) 0.982 (0.814–1.18)
Abbreviations: AUC0-τ area under the concentration-time curve over the dosing interval, Cτ concentration at the end of the dosing interval, CI confidence interval,
CL/F apparent clearance following oral dosing, Cmax maximum observed concentration, CV% coefficient of variation, DCV daclatasvir, DTG dolutegravir,
PK pharmacokinetic, t1/2 terminal phase half-life
Treatment B = DCV 60 mg once daily; treatment C = DTG 50 mg once daily plus DCV 60 mg once daily
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dose adjustment is necessary when it is coadministered
with DCV.
Conclusions
In conclusion, since DTG and DCV were well tolerated
when given alone or in combination and no clinically
significant increases in plasma exposure for either drug
were observed, these results indicate that DTG and DCV
can be coadministered without dose adjustment.
Abbreviations
AE, adverse event; AUC0-τ, area under the concentration-time curve over a
dosing interval; BCRP, breast cancer resistance protein; C0, predose DTG
concentrations; CI, confidence interval; CL/F, apparent clearance following oral
dosing; Cmax, maximum observed concentration; CV, coefficient of variance;
CVw, within-subject variability; CYP, cytochrome P450; Cτ, concentration at the
end of the dosing interval; DCV, daclatasvir; DTG, dolutegravir; HCV, hepatitis C
virus; K2 EDTA, potassium ethylenediaminetetraacetic acid; P-gp, P-glycoprotein;
PK, pharmacokinetic; QC, quality control; SD, standard deviation; t1/2, terminal
phase half-life
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